Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 37331369

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2023 Jul 1
First author
Dasari A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2023 Jul 1;402(10395):4-5. doi: 10.1016/S0140-6736(23)00867-X.
    note
    Source null
    related pmid
    37331366
    relationship
    Comment in
  2. citation
    Transl Cancer Res. 2023 Dec 31;12(12):3241-3244. doi: 10.21037/tcr-23-1568.
    note
    Source null
    related pmid
    38192992
    relationship
    Comment in

Authors and identifiers

  1. name
    Dasari A
    type
    Author
  2. name
    Lonardi S
    type
    Author
  3. name
    Garcia-Carbonero R
    type
    Author
  4. name
    Elez E
    type
    Author
  5. name
    Yoshino T
    type
    Author
  6. name
    Sobrero A
    type
    Author
  7. name
    Yao J
    type
    Author
  8. name
    García-Alfonso P
    type
    Author
  9. name
    Kocsis J
    type
    Author
  10. name
    Cubillo Gracian A
    type
    Author
  11. name
    Sartore-Bianchi A
    type
    Author
  12. name
    Satoh T
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Dasari A
    type
    Author
  2. name
    Lonardi S
    type
    Author
  3. name
    Garcia-Carbonero R
    type
    Author
  4. name
    Elez E
    type
    Author
  5. name
    Yoshino T
    type
    Author
  6. name
    Sobrero A
    type
    Author
  7. name
    Yao J
    type
    Author
  8. name
    García-Alfonso P
    type
    Author
  9. name
    Kocsis J
    type
    Author
  10. name
    Cubillo Gracian A
    type
    Author
  11. name
    Sartore-Bianchi A
    type
    Author
  12. name
    Satoh T
    type
    Author
bibliography ids
  1. nci-bib-bdd271eb724b9103493eccc2
book metadata
content sha256
c00e560985eb57a15cd341984eff76489a894e44e0a483d20b0cb6e3a4d153c9
document type
citation
dois
  1. 10.1016/S0140-6736(23)00772-9
electronic publication date
display
2023 Jun 15
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:37331369
immutable id
pubmed:37331369@c00e560985eb57a15cd341984eff76489a894e44e0a483d20b0cb6e3a4d153c9
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10395
name
Lancet (London, England)
nlm unique id
2985213R
pages
41-53
volume
402
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2023 Jul 1;402(10395):4-5. doi: 10.1016/S0140-6736(23)00867-X.
    note
    Source null
    related pmid
    37331366
    relationship
    Comment in
  2. citation
    Transl Cancer Res. 2023 Dec 31;12(12):3241-3244. doi: 10.21037/tcr-23-1568.
    note
    Source null
    related pmid
    38192992
    relationship
    Comment in
outcomes validated
false
pmid
37331369
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
e5bb5929d0475914412a8cd57fce6c238d2932a369928ce0c73c5ed18b56fa48
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 Jul 1
precision
day
year
2023
publication types
  1. Randomized Controlled Trial
  2. Clinical Trial, Phase III
  3. Multicenter Study
  4. Journal Article
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37331369/
title
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.

Preserved source evidence · Independent clinical review pending · Not medical advice